Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

Since the late 1980s, mutations in the RAS genes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch in a constitutively active GTP-bound form that drives, unch...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillig, Roman C., Sautier, Brice, Schroeder, Jens, Moosmayer, Dieter, Hilpmann, André, Stegmann, Christian M., Werbeck, Nicolas D., Briem, Hans, Boemer, Ulf, Weiske, Joerg, Badock, Volker, Mastouri, Julia, Petersen, Kirstin, Siemeister, Gerhard, Kahmann, Jan D., Wegener, Dennis, Böhnke, Niels, Eis, Knut, Graham, Keith, Wortmann, Lars, von Nussbaum, Franz, Bader, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2019
Materias:
PNAS Plus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377443/
https://www.ncbi.nlm.nih.gov/pubmed/30683722
http://dx.doi.org/10.1073/pnas.1812963116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377443/
https://www.ncbi.nlm.nih.gov/pubmed/30683722
http://dx.doi.org/10.1073/pnas.1812963116

Ejemplares similares